Drugs / Sulfur Hexafluoride Lipid Microspheres
Sulfur Hexafluoride Lipid Microspheres
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03407001 | Jan 2018 → Sep 2020 | cirrhosis of liver | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05641935 | Nov 2022 → Aug 2027 expected | renal cell carcinoma | john eisenbrey | Recruiting | No outcome recorded |
| Phase 2 | NCT04021238 | Oct 2020 → Aug 2022 | kidney cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03907657 | Sep 2019 → Mar 2023 | chronic kidney disease, von Hippel-Lindau disease | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03300401 | Nov 2017 → Nov 2019 | hepatocellular carcinoma | University of Southern California | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06171607 Background | Nov 2020 → Nov 2026 expected | breast carcinoma | University of Southern California | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulfur Hexafluoride Lipid Microspheres | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05641935 ↗ |
| Modality | Diagnostic / imaging agent | “contrast-agent consisting of microbubbles” NCT03300401 ↗ |
| Route | Intravenous | “Receive intravenous injection just prior to ultrasound” NCT03300401 ↗ |